NEWTOWN, Pa. - Traws Pharma, Inc. (NASDAQ:TRAW), a clinical-stage biopharmaceutical company, announced the appointment of Luba Greenwood to its Board of Directors. Concurrently, the company is bidding farewell to long-serving Director James J. Marino, who is stepping down after a decade with the company, including four years as Chairman.
Luba Greenwood, recognized for her extensive experience in the life sciences sector, joins Traws Pharma's board with a background that includes strategic advisory roles and executive positions across various healthcare organizations. Greenwood's previous roles include serving as Managing Partner at Binney Street Capital and Vice President of Global Business Development and M&A at Roche.
The company is currently advancing its pipeline of oral small molecule therapies, with a focus on respiratory viral diseases and cancer. Traws Pharma's viral respiratory disease program includes two oral small molecules in Phase 1 studies: tivoxavir marboxil for influenza and avian flu, and ratutrelvir for COVID-19. In the oncology field, Traws is developing a multi-kinase CDK4-plus inhibitor, narazaciclib, and rigosertib, targeting cell cycle proteins including PLK-1.
The appointment of Greenwood is part of Traws Pharma's ongoing transformation and growth strategy, which includes progressing novel respiratory antiviral therapies through clinical trials and advancing its oncology strategy. The company has also been working on merging with Trawsfynydd, a company founded by the i2020 Accelerator, since April 2024.
Iain Dukes, PhD, Executive Chairman of Traws Pharma, expressed confidence that Greenwood's expertise would be invaluable as the company embarks on its next phase of development. He also extended gratitude to Marino for his significant contributions over the years.
The company has emphasized its commitment to addressing unmet medical needs by developing novel compounds, with a focus on product safety and support for vulnerable patients. Traws Pharma has made forward-looking statements regarding its business and product candidates, which are subject to risks and uncertainties.
The information in this article is based on a press release statement from Traws Pharma, Inc.
In other recent news, Traws Pharma faces potential delisting from the Nasdaq due to an equity shortfall of approximately $105.5 million, falling short of the required $2.5 million equity threshold. The company has been given until October 7, 2024, to submit a plan to regain compliance. In other developments, Traws Pharma has engaged KPMG LLP as its new independent registered public accounting firm, a move aimed at maintaining robust financial practices.
The company has also amended its corporate bylaws, lowering the quorum requirement for stockholder meetings, potentially facilitating easier decision-making. In a significant move, Traws Pharma announced a merger with Onconova Therapeutics (NASDAQ:TRAW) and Trawsfynydd Therapeutics, aiming to advance potential assets in viral diseases and cancer treatment development. The merger is expected to provide Traws Pharma with an estimated $28 million cash balance.
However, the company also reported the immediate resignation of Steven M. Fruchtman, the company's President and Chief Scientific Officer, Oncology. The board disagrees with Fruchtman's characterization of the events leading to his resignation and believes that the circumstances do not warrant severance payments under the terms of his employment agreement. These are the latest developments in Traws Pharma's operations.
InvestingPro Insights
As Traws Pharma, Inc. (NASDAQ:TRAW) welcomes Luba Greenwood to its Board of Directors, the company's financial health and stock performance provide a backdrop to its strategic decisions. With a market capitalization of 7.85 million USD, Traws Pharma holds a unique position in the biopharmaceutical space. Notably, the company's gross profit margin stands at an impressive 100% as of the last twelve months leading up to Q2 2024, reflecting the efficiency of its revenue conversion into gross profit.
However, despite this strong margin, Traws Pharma faces significant challenges. The company's operating income margin for the same period is deeply negative at -9135.84%, indicating substantial operating costs relative to its revenue. This is further reflected in the company's basic and diluted EPS (Continuing Operations), both reported at -6.2 USD. Such figures underscore the financial hurdles the company must overcome as it advances its clinical pipeline.
InvestingPro Tips highlight a few critical aspects for current and potential investors. Traws Pharma is expected to see net income growth this year, which could signal a turning point for the company's profitability. Moreover, analysts predict that the company will become profitable within the year, a prospect that could bolster investor confidence.
In terms of stock performance, Traws Pharma has experienced a significant decline over the last six months, with a price total return of -62.92%. This trend may concern investors, although it could also present a buying opportunity for those who believe in the company's long-term potential.
For investors interested in deeper analysis and additional insights, InvestingPro offers a comprehensive list of tips, including a total of 11 InvestingPro Tips for Traws Pharma, which can be found at https://www.investing.com/pro/TRAW. These tips could provide valuable guidance for making informed investment decisions in the context of the company's strategic growth and development.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.